Knebel, Birgit

Empagliflozin effectively lowers liver fat content in well-controlled type 2 diabetes: a randomized, double-blind, phase 4, placebo-controlled trial

Kahl, S., Gancheva, S., Straßburger, K., Herder, C., Machann, J., Katsuyama, H., Kabisch, S., Henkel, E., Kopf, S., Lagerpusch, M., et al. (2020) · Diabetes Care

Diabetes Treatment and ManagementLiver Disease Diagnosis and Treatment

Cited by 360

Liver-specific expression of transcriptionally active SREBP-1c is associated with fatty liver and increased visceral fat mass

Knebel, B., Haas, J., Hartwig, S., Jacob, S., Köllmer, C., Nitzgen, U., Muller–Wieland, D., & Kotzka, J. (2012) · PLoS ONE

Liver Disease Diagnosis and TreatmentLipid metabolism and biosynthesis

Cited by 162

Mechanisms of Insulin Resistance in Primary and Secondary Nonalcoholic Fatty Liver

Jelenik, T., Kaul, K., Séquaris, G., Flögel, U., Phielix, E., Kotzka, J., Knebel, B., Fahlbusch, P., Hörbelt, T., Lehr, S., et al. (2017) · Diabetes

Liver Disease Diagnosis and TreatmentDiet, Metabolism, and Disease

Cited by 154

Liver lipid droplet cholesterol content is a key determinant of metabolic dysfunction–associated steatohepatitis

Sakuma, I., Gaspar, R. C., Nasiri, A. R., Dufour, S., Kahn, M., Zheng, J., LaMoia, T. E., Guerra, M. T., Taki, Y., Kawashima, Y., et al. (2025) · Proceedings of the National Academy of Sciences

Liver Disease Diagnosis and TreatmentCholesterol and Lipid Metabolism

Cited by 46

Lipodystrophies—Disorders of the Fatty Tissue

Knebel, B., Müller-Wieland, D., & Kotzka, J. (2020) · International Journal of Molecular Sciences

Adipose Tissue and MetabolismLipid metabolism and disorders

Cited by 39